Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-ROR1/anti-CD3 bispecific antibody EMB-07

A bispecific antibody directed against both the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-ROR1/anti-CD3 bispecific antibody EMB-07 binds to both ROR1 expressed on tumor cells and CD3 expressed on cytotoxic T lymphocytes (CTLs). This activates and redirects CTLs to ROR1-expressing tumor cells, which results in the CTL-mediated death of ROR1-expressing tumor cells. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and in many types of hematological malignancies. It plays key roles in tumor cell proliferation and survival.
Synonym:anti-ROR1/CD3 bispecific antibody EMB-07
ROR1 x CD3 bispecific antibody EMB-07
Code name:EMB 07
EMB-07
EMB07
Search NCI's Drug Dictionary